ClinicalTrials.gg
RecruitingNCT07211620KIPRUNUpdated Nov 3, 2026

KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use - Comparing Procalcitonin Kinetics-guided and Absolute Procalcitonin Value-guided Antibiotic Initiation in Reducing Unnecessary Antibiotic Use in Critically Ill Patients

An interventional study of Kinetics and Absolute in Infection and Sepsis, sponsored by Semmelweis University. Recruiting at 2 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionSepsisRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sepsis
Why
  1. The study's listed conditions name Sepsis, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Semmelweis University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Sepsis with a site in Hungary — 4 open to participants now, 4 under way, none of them phase 3. Sepsis · Hungary.

Planned enrollment
6th of 16
250 · median 130
Started
2025
the only one that year
No phase
2 of 22
2 open now
Registered
19th of 22
by date
Lead sponsor
3 of 22
Semmelweis University

Among the 22 studies in Sepsis with a site in Hungary, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 19th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

4 of the 22 studies in Sepsis with a site in Hungary are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Hungary have not opened yet or have stopped. Only those recruiting at a site in Hungary →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Sepsis with a site in Hungary, or all of them as a file.
02

Study summary

The study aims to compare the efficacy and safety of an absolute procalcitonin (PCT) value-guided antibiotic initiation protocol and a protocol using the kinetics of PCT (the difference between the actual and the previous day value) in hemodynamically stable critically ill patients with suspected new-onset infection on admission or during ICU stay.

The main question it aims to answer:

  • Can the investigators decrease the number of unnecessary AB therapies using the kinetics of PCT insted of using absolute PCT values?
  • Is it safe to use PCT kinetics together with the clinical picture to guide AB initiation? AB therapy will be initiated according to predefined PCT protocols (Kinetics and Absolute Group). After 72 hours of treatment, an independent multidisciplinary team (infectologist, microbiologist and intensivist) will decide about the necessity of the treatment with all the relevant results in hand.
Read the detailed description

Appropriate antibiotic (AB) therapy is still a big challenge in intensive care units today. More than 50% of our patients are considered potentially infected, and infection alone can double mortality; however, infection is later confirmed in less than 60% of patients admitted with the initial diagnosis of sepsis. According to previous studies, at least every fifth patient in intensive care units receives unnecessary antibiotics (ABs), leading to the well-known adverse effects of ABs without any benefit. The emergence of AB resistance has been associated with 700,000 avoidable deaths in 2014, and WHO estimates that it will contribute to the death of 10 million people by 2050.

Procalcitonin (PCT) is one of the most studied inflammatory biomarkers. Several randomized controlled trials (RCTs) and their meta-analyses concluded that PCT-guided antibiotic treatment could reduce the length of AB therapy without adverse effects; moreover, it may be associated with reduced 28-day mortality, which was also confirmed by our study in 2023. Accordingly, the current sepsis guideline recommends the combined evaluation of the clinical picture and PCT when stopping AB therapy; however, it contains a weak recommendation against using PCT when starting the treatment. The latter proposition is based on three studies with a significant number of surgical patients (around 40%) in two of them, in whom the applied PCT cut-off (0.5-1 ng/ml) presumably was too low, supported by several previous studies. Therefore, the overuse of ABs was more or less hardcoded into the protocol.

Kinetics of an inflammatory biomarker can carry much more information about the host response to infection instead of a single value. In a prospective observational study by Trasy et al., early PCT kinetics (PCT change between the day of suspected infection and the previous 24 hours) predicted infection, while PCT did not change in the group of patients in whom the infection was later ruled out. Tsangaris and his colleagues measured PCT daily in critically ill patients. The investigators noted a two-fold increase in PCT levels between the day of fever onset and the previous day if the patients had an infection, while there was no difference in the PCT values if the participants had no infection.

Based on these findings, the investigators created a protocol to reduce the number of unnecessary antibiotic therapies using the kinetics of PCT.

03

Conditions studied

  • Infection
  • Sepsis

Browse trials for

Keywords

  • procalcitonin
  • bacterial infection
  • antibiotics
  • kinetics
04

In context

Sepsis Reclassified

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

This study's planned enrollment of 250 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.

Compared within Sepsis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (18 years \< ) non-surgical, surgical, or trauma patients
  • Suspected new-onset infection on admission or during ICU stay
  • The source of infection is known or highly suspected, and source control has been implemented if needed (i.e., removal of an infected device (e.g., central line, endoprosthesis)
  • Two PCT values are available - one on the day of suspicion of infection and one 24±4 hours earlier.
  • Microbiology sampling has to be performed (according to all presumed sources - blood culture -aerobic and anaerobic, lower respiratory tract sample (tracheal aspirate/bronchoalveolar lavage), urine, etc.).
  • Written of the patient (or legal guardian if the patient cannot provide consent)

Exclusion criteria

Exclusion Criteria:

  • Septic shock (hypotension requiring vasopressor therapy to maintain mean blood pressure of 65 mmHg or greater and having a serum lactate level greater than 2 mmol/L after adequate fluid resuscitation)
  • Infections for which long-term antibiotic treatment is strongly recommended (e.g., infective endocarditis, osteoarticular infections, chronic prostatitis, tuberculosis)
  • Infections related to primary surgical intervention and adequate source control cannot be guaranteed (e.g., fecal peritonitis, pancreatic necrosectomy, infective necrotizing fascitis - i.e., Fournier's gangrene),
  • Indisputable infections (e.g., hepatic abscess, empyema)
  • Poor chance of survival (i.e., expected ICU stay less than 24 hours or initial Acute Physiology and Health Evaluation Score II (APACHE II) >30)
  • Admissions after cardiopulmonary resuscitation
  • Severe other than use
  • stem-cell transplant recipients
  • solid organ transplant patients
  • infection with a of less than 200 cells/mm3
  • Neutropenia with less than 500 neutrophils/mm3
  • Patients on ABs within 72 hours before inclusion
  • Patients in pregnancy or breastfeeding. Women of childbearing age will be screened by a urine pregnancy test before inclusion in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Kinetics

    In the case of a suspected new-onset infection, the treating physician starts antibiotic therapy according to a predefined protocol depending on the kinetics of PCT.

    Other: Kinetics

  • Experimental
    Absolute

    In the case of a new-onset infection, starting ABs is recommended depending on the actual absolute value of PCT.

    Other: Absolute

Interventions

  • OtherKinetics

    Initiation of the AB therapy is recommended for the clinician if PCT ≥ 0.5 ng/ml and PCT elevation ≥100% from the previous day's value.

  • OtherAbsolute

    According to the antibiotic protocol, starting ABs is recommended if PCT ≥ 0.5 ng/ml.

07

What researchers measure

Primary outcomes

  1. Rate of unnecessary antibiotic therapy

    The number of unjustified antibiotic therapies divided by the number of all therapies.

    Time frame: From date of enrollment until 72 hours.

Secondary outcomes

  1. Organ-support free days

    Number of days alive without life support - mechanical ventilation, vasoactive therapy and renal replacement therapy.

    Time frame: From date of enrollment until the date of disharge of the patient from the ICU or the date of patient's death from any cause, whichever came first, assessed up to 6 months.

  2. Lenght of stay at the intensive care unit

    Number of days the patient stays at ICU

    Time frame: From date of enrollment until the date of discharge of patient from the ICU or the date of patient's death from any cause, whichever came first, assessed up to 6 months.

  3. Length of stay in hospital

    Number of days the patient stays in the hospital

    Time frame: From date of enrollment until the date of hospital discharge of the patient or the date of patient's death from any cause, whichever came first, assessed up to 6 months.

  4. Duration of mechanical ventilation

    Duration of mechanical ventilation in days

    Time frame: From date of enrollment until date of ICU discharge of the patient or date of patient's death from any cause, whichever came first, asessed up to 6 months.

  5. Duration of renal replacement therapy

    Duration of renal replacement therapy in days

    Time frame: From date of enrollment until date of hospital discharge of the patient or date of patient's death from any cause, whichever came first, assessed up to 6 months.

  6. Duration of catecholamine circulatory support

    Duration of catecholamine circulatory support in days

    Time frame: From date of enrollment until date of ICU discharge of the patient or date of patient's death from any cause, whichever came first, assessed up to 6 months.

  7. ICU mortality

    The number of patients died during ICU stay devided by the number of patients enrolled.

    Time frame: From date of enrollment until the date of ICU discharge of the patient, assessed up to 6 months.

  8. 28-day mortality

    The number of patients died divided by the number of patients enrolled.

    Time frame: From date of enrollment until day 28.

  9. In-hospital mortality

    The number of patients died devided by the number of patients enrolled.

    Time frame: From date of enrollment until hospital discharge of the patient, assessed up to 6 months.

  10. Number of Multidrug-resistant Organism caused infections

    Number of diagnosed infections caused by bacteria that are resistant to one or more classes of antimicrobial agents.

    Time frame: From date of enrollment until the date of hospital discharge of the patient or the patient's death from any cause, whichever came first, assessed up to 6 months.

  11. Number of Clostridioides difficile infections

    Number of verified Clostridioides difficile infections

    Time frame: From date of enrollment until the date of hospital discharge of the patient or the patient's death from any cause, whichever came first, assessed up to 6 months.

08

Study locations

1 of 2 sites recruiting
09

References and documents

Publications

  • Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289. PubMed 26903336 ↗
  • Tsangaris I, Plachouras D, Kavatha D, Gourgoulis GM, Tsantes A, Kopterides P, Tsaknis G, Dimopoulou I, Orfanos S, Giamarellos-Bourboulis E, Giamarellou H, Armaganidis A. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis. 2009 Dec 22;9:213. doi: 10.1186/1471-2334-9-213. PubMed 20028533 ↗
  • Trasy D, Tanczos K, Nemeth M, Hankovszky P, Lovas A, Mikor A, Hajdu E, Osztroluczki A, Fazakas J, Molnar Z. Delta Procalcitonin Is a Better Indicator of Infection Than Absolute Procalcitonin Values in Critically Ill Patients: A Prospective Observational Study. J Immunol Res. 2016;2016:3530752. doi: 10.1155/2016/3530752. Epub 2016 Aug 15. PubMed 27597981 ↗
  • Szakmany T, Molnar Z. Procalcitonin levels do not predict mortality following major abdominal surgery. Can J Anaesth. 2003 Dec;50(10):1082-3. doi: 10.1007/BF03018387. No abstract available. PubMed 14656802 ↗
  • Trasy D, Tanczos K, Nemeth M, Hankovszky P, Lovas A, Mikor A, Laszlo I, Hajdu E, Osztroluczki A, Fazakas J, Molnar Z; EProK study group. Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: A prospective observational study. J Crit Care. 2016 Aug;34:50-5. doi: 10.1016/j.jcrc.2016.04.007. Epub 2016 Apr 13. PubMed 27288610 ↗
  • Najafi A, Khodadadian A, Sanatkar M, Shariat Moharari R, Etezadi F, Ahmadi A, Imani F, Khajavi MR. The Comparison of Procalcitonin Guidance Administer Antibiotics with Empiric Antibiotic Therapy in Critically Ill Patients Admitted in Intensive Care Unit. Acta Med Iran. 2015;53(9):562-7. PubMed 26553084 ↗
  • Layios N, Lambermont B, Canivet JL, Morimont P, Preiser JC, Garweg C, Ledoux D, Frippiat F, Piret S, Giot JB, Wiesen P, Meuris C, Massion P, Leonard P, Nys M, Lancellotti P, Chapelle JP, Damas P. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med. 2012 Aug;40(8):2304-9. doi: 10.1097/CCM.0b013e318251517a. PubMed 22809906 ↗
  • Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, Tousi H, Soe-Jensen P, Lauritsen AO, Strange D, Petersen PL, Reiter N, Hestad S, Thormar K, Fjeldborg P, Larsen KM, Drenck NE, Ostergaard C, Kjaer J, Grarup J, Lundgren JD; Procalcitonin And Survival Study (PASS) Group. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011 Sep;39(9):2048-58. doi: 10.1097/CCM.0b013e31821e8791. PubMed 21572328 ↗
  • Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Moller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143. doi: 10.1097/CCM.0000000000005337. No abstract available. PubMed 34605781 ↗
  • Papp M, Kiss N, Baka M, Trasy D, Zubek L, Fehervari P, Harnos A, Turan C, Hegyi P, Molnar Z. Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis. Crit Care. 2023 Oct 13;27(1):394. doi: 10.1186/s13054-023-04677-2. PubMed 37833778 ↗
  • de Kraker ME, Stewardson AJ, Harbarth S. Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med. 2016 Nov 29;13(11):e1002184. doi: 10.1371/journal.pmed.1002184. eCollection 2016 Nov. PubMed 27898664 ↗
  • Montravers P, Dupont H, Gauzit R, Veber B, Bedos JP, Lepape A; Club d'Infectiologie en Anesthesie-Reanimation Study Group. Strategies of initiation and streamlining of antibiotic therapy in 41 French intensive care units. Crit Care. 2011;15(1):R17. doi: 10.1186/cc9961. Epub 2011 Jan 13. PubMed 21232098 ↗
  • Klein Klouwenberg PM, Cremer OL, van Vught LA, Ong DS, Frencken JF, Schultz MJ, Bonten MJ, van der Poll T. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care. 2015 Sep 7;19(1):319. doi: 10.1186/s13054-015-1035-1. PubMed 26346055 ↗
  • Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, Finfer S, Pelosi P, Brazzi L, Aditianingsih D, Timsit JF, Du B, Wittebole X, Maca J, Kannan S, Gorordo-Delsol LA, De Waele JJ, Mehta Y, Bonten MJM, Khanna AK, Kollef M, Human M, Angus DC; EPIC III Investigators. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA. 2020 Apr 21;323(15):1478-1487. doi: 10.1001/jama.2020.2717. PubMed 32207816 ↗
  • Papp M, Turan C, Kiss N, Zubek L, Karim DM, Hegyi P, Molnar Z. KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic use (KIPRUN): protocol for a multicentre, randomised, superiority trial to compare the efficacy and safety of procalcitonin kinetics-guided and absolute procalcitonin value-guided antibiotic initiation in critically ill patients. BMJ Open. 2026 May 13;16(5):e115344. doi: 10.1136/bmjopen-2025-115344. PubMed 42128499 ↗

Individual participant data

Plan to share: Yes — All data obtained through the study may be provided to researchers with an interest in optimizing antibiotic therapy of critically ill patients. Data and samples will be coded if shared with no protected health information included. Zsolt Molnár will receive invitations/requests to share individual participant data, and will consider if the request: 1) explicitly serves public benefit, 2) complies with local ethical and data security regulations of the requesting and providing institutions, 3) lays out the existing or planned legal and technical infrastructure for data transfer, 4) provides a publicly available protocol for planned statistical analyses.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 303 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 25 months is close to that.

Counting every sponsor, half of 326 studies reached it within 22 months; a quarter within 11 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2025
First posted
Oct 8, 2025
StartActual
Nov 6, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07211620
Responsible party
Dr. Papp Márton (co-head of the unit, Semmelweis University) — Principal investigator
First posted
Oct 8, 2025
Start date
Nov 6, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Márton Papp
Contact
papp.marton@semmelweis.hu
+36206663224
Zsolt Molnár
Contact
molnar.zsolt1@semmelweis.hu
+36303026668
Nikolett Kiss
study chair · Semmelweis University
László Zubek
study chair · Semmelweis University
Caner Turan
study chair · Semmelweis University
Dilan M. Karim
study chair · Semmelweis University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion